Identifying nursing home residents at high risk for preventable adverse drug events: Modifying a tool for use in the fleetwood phase III study

Consultant Pharmacist

Volumn 19, Issue 6, 2004, Pages 533-537

  Lapane, Kate L ^a   Hughes, Carmel M ^b  

^a BROWN UNIVERSITY   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Adverse drug events; Fleetwood Phase III study; Geriatrics; High risk screening; Long term care

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; HYPNOTIC SEDATIVE AGENT; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; OPIATE;

ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NURSING HOME; PHARMACIST; PHASE 3 CLINICAL TRIAL; RISK FACTOR; SCREENING TEST; UNITED STATES;

EID: 3042810391     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2004.533     Document Type: Article

References (14)

1. Hanlon J, Schmader K, Ruby C et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49:200-9.
2. Gurwitz JH, Soumerai SB, Avorn J. Improving medication prescribing and utilization in the nursing home. J Am Geriatr Soc 1990;38:542-52.
3. Dhall J, Larrat EP, Lapane KL. Potentially inappropriate medication use in nursing homes. Pharmacotherapy 2002;22:88-96.
4. Bernabei R, Gambassi G, Lapane KL et al. Characteristics of the SAGE Database. A new resource for research on outcomes in long-term care. J Gerontol A Biol Sci Med Sci 1999;54:M25-M33.
5. Avorn JA, Gurwitz JH. Drug use the nursing home. Ann Intern Med 1995; 123: 195-204.
6. Lamy PP. Physiological changes due to age. Drugs Aging 1991;5:385-404.
7. Office of the Inspector General. Prescription drug use in nursing homes, in Report 2: an inside view by consultant pharmacists. Department of Health and Human Services Report No. OEI-06-96-00081, 1997.
8. Gurwitz JH, Field TS, Avorn j et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109:87-94.
9. Bootman JL, Harrison DL, Cox E. The health care cost o of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157:2089-96.
10. Daschner M, Brownstein S, Cameron KA et al. Fleetwood Phase 11 tests a new model of long-term care pharmacy. Consult Pharm 2000;15:989-1005.
11. Cameron K, Feinberg JL, Lapane KL. Fleetwood Project Phase III moves forward. Consult Pharm 2002;17:181-98.
12. Fouts M, Hanlon J, Pieper C et al. Identification of elderly nursing facility residents at high risk for drug-related problems. Consult Pharm 1997;12:1103-11.
13. Field TS, Gurwitz JH, Avorn J et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001;161:629-34.
14. Stoudemire A, Smith DA. OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Gen Hosp Psychiatry 1996;18:77-94